Financial reports
Current reports
6-K
Report of Foreign Private Issuer
2 Jan 24
6-K
Form of Letter of Lock-up Undertaking
15 Dec 23
6-K
Regencell Bioscience Holdings Limited Announces First Half 2023 Management Financial Results
15 Jun 23
6-K
SECOND EXTENSION OF letter of Lock-Up Undertaking
5 Jun 23
6-K
Report of Foreign Private Issuer
17 Mar 23
6-K
Report of Foreign Private Issuer
28 Feb 23
6-K
Report of Foreign Private Issuer
4 Jan 23
6-K
Report of Foreign Private Issuer
22 Dec 22
6-K
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
12 Sep 22
6-K
Regencell Bioscience Holdings Limited Announces First Half 2022 Management Financial Results
2 Jun 22
Registration and prospectus
424B4
Prospectus supplement with pricing info
20 Jul 21
8-A12B
Registration of securities on exchange
15 Jul 21
FWP
Free writing prospectus
8 Jul 21
FWP
Free writing prospectus
30 Jun 21
F-1/A
Registration statement (foreign) (amended)
23 Jun 21
F-1/A
Registration statement (foreign) (amended)
11 Jun 21
F-1/A
Registration statement (foreign) (amended)
26 Apr 21
F-1
Registration statement (foreign)
22 Mar 21
DRS/A
Draft registration statement (amended)
4 Feb 21
DRSLTR
Correspondence regarding draft registration statement
3 Feb 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
16 Jul 21
CERT
Certification of approval for exchange listing
15 Jul 21
CORRESP
Correspondence with SEC
13 Jul 21
CORRESP
Correspondence with SEC
13 Jul 21
CORRESP
Correspondence with SEC
22 Jun 21
UPLOAD
Letter from SEC
21 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
UPLOAD
Letter from SEC
3 May 21
CORRESP
Correspondence with SEC
26 Apr 21
UPLOAD
Letter from SEC
5 Apr 21